Zacks: Analysts Expect Exponent, Inc. (EXPO) Will Post Quarterly Sales of $88.46 Million

Equities analysts predict that Exponent, Inc. (NASDAQ:EXPO) will report sales of $88.46 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Exponent’s earnings. The lowest sales estimate is $88.22 million and the highest is $88.70 million. Exponent posted sales of $84.12 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5.2%. The business is expected to announce its next earnings report after the market closes on Thursday, July 19th.

On average, analysts expect that Exponent will report full year sales of $355.00 million for the current fiscal year, with estimates ranging from $353.80 million to $356.20 million. For the next fiscal year, analysts expect that the business will post sales of $378.03 million per share, with estimates ranging from $371.00 million to $385.05 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Exponent.

Exponent (NASDAQ:EXPO) last issued its quarterly earnings results on Thursday, April 19th. The business services provider reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. Exponent had a return on equity of 19.47% and a net margin of 12.52%. The firm had revenue of $96.50 million during the quarter, compared to the consensus estimate of $87.54 million. During the same period last year, the company earned $0.15 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis.

Several brokerages recently weighed in on EXPO. ValuEngine raised Exponent from a “hold” rating to a “buy” rating in a report on Tuesday, April 3rd. Zacks Investment Research raised Exponent from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Tuesday, February 27th. SunTrust Banks increased their price target on Exponent to $23.75 and gave the stock a “buy” rating in a report on Monday, April 23rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $24.00 price target on shares of Exponent in a report on Friday, April 20th. Finally, BidaskClub raised Exponent from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 14th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Exponent has a consensus rating of “Buy” and a consensus target price of $23.92.

Shares of Exponent traded up $0.65, hitting $50.25, during mid-day trading on Tuesday, according to Marketbeat Ratings. 413,126 shares of the company were exchanged, compared to its average volume of 297,815. Exponent has a 1-year low of $28.48 and a 1-year high of $52.63. The company has a market cap of $2.58 billion, a PE ratio of 46.96 and a beta of 0.64.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 22nd. Shareholders of record on Friday, June 8th were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date was Thursday, June 7th. Exponent’s dividend payout ratio (DPR) is currently 48.60%.

In other Exponent news, Director Debra Zumwalt sold 500 shares of the firm’s stock in a transaction on Friday, May 25th. The stock was sold at an average price of $96.01, for a total value of $48,005.00. Following the completion of the sale, the director now owns 6,940 shares of the company’s stock, valued at $666,309.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Harri Kytomaa sold 2,639 shares of the firm’s stock in a transaction on Friday, May 18th. The shares were sold at an average price of $94.04, for a total value of $248,171.56. Following the completion of the sale, the insider now directly owns 8,045 shares of the company’s stock, valued at approximately $756,551.80. The disclosure for this sale can be found here. In the last three months, insiders sold 40,262 shares of company stock valued at $3,586,801. 2.80% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. lifted its holdings in Exponent by 5.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 32,775 shares of the business services provider’s stock valued at $2,330,000 after acquiring an additional 1,836 shares during the period. Comerica Bank raised its stake in shares of Exponent by 17.5% during the 4th quarter. Comerica Bank now owns 41,815 shares of the business services provider’s stock worth $3,042,000 after buying an additional 6,213 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Exponent during the 4th quarter worth $628,000. Raymond James Financial Services Advisors Inc. raised its stake in shares of Exponent by 3.8% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 57,282 shares of the business services provider’s stock worth $4,073,000 after buying an additional 2,097 shares during the last quarter. Finally, Crestline Management LP acquired a new position in shares of Exponent during the 4th quarter worth $1,979,000. 43.59% of the stock is owned by institutional investors.

About Exponent

Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.

Get a free copy of the Zacks research report on Exponent (EXPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exponent (NASDAQ:EXPO)

Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply